Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

12

Revenue 2017

Bayer

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Bayer's 2013 sales performance.

Bayer

Finalists

Switch 4 Them” - Protecting Vulnerable Patients During a Pandemic. by Bayer.

Amgen, Cytokinetics’ heart failure drug disappoints in phase 3

Amgen, Cytokinetics’ heart failure drug disappoints in phase 3 Also coming through the pipeline is Merck &Co and Bayer’s high-risk heart failure drug vericiguat which is currently being studied in patients with worsening chronic heart failure with reduced

Switzerland: a life sciences hub

Switzerland: a life sciences hub The country is thus home to AbbVie, Allergan, Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Lundbeck, MSD (Merck Sharp &Dohme), Pfizer, Sanofi and Takeda among others.

AI: the smart money is on the smart thinking

AI: the smart money is on the smart thinking Bayer and Merck &Co provide a perfect example of this. They have developed an AI software system to support clinical decision-making of chronic thromboembolic pulmonary hypertension (CTEPH) – a rare form ... Bayer and Merck &Co hope that radiologists

Merck, Bayer get FDA priority review for heart failure drug

Merck, Bayer get FDA priority review for heart failure drug Despite the mixed results, Merck and Bayer decided to take their chances and advanced the vericiguat clinical programme into phase 3. ... clinicians. With the FDA priority review in their pocket, Merck and Bayer can expect a decision by 20 January 2021.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics